Table 4 Treatment analysis of patients with high BILAG-2004 and low SLEDAI-2000 scores with different cut-off scores used to define active disease with SLEDAI-2000
Treatment increasedTreatment reducedTreatment not changed
BILAG-2004 A or B and SLEDAI-2000 <10 (n = 37)18 (48.7%)4 (10.8%)15 (40.5%)
BILAG-2004 A or B and SLEDAI-2000 <9 (n = 37)18 (48.7%)4 (10.8%)15 (40.5%)
BILAG-2004 A or B and SLEDAI-2000 <8 (n = 35)17 (48.6%)3 (8.6%)15 (42.9%)
BILAG-2004 A or B and SLEDAI-2000 <7 (n = 35)17 (48.6%)3 (8.6%)15 (42.9%)
BILAG-2004 A or B and SLEDAI-2000 <6 (n = 35)17 (48.6%)3 (8.5%)15 (42.9%)
BILAG-2004 A or B and SLEDAI-2000 <5 (n = 30)15 (50%)3 (10%)12 (40%)
BILAG-2004 A or B and SLEDAI-2000 <4 (n = 16)9 (56.3%)07 (43.7%)
BILAG-2004 A or B and SLEDAI-2000 <3 (n = 16)9 (56.3%)07 (43.7%)
BILAG-2004 A or B and SLEDAI-2000 <2 (n = 16)2 (50%)02 (50%)
BILAG-2004 A or B and SLEDAI-2000  = 0 (n = 4)2 (50%)02 (50%)

  • BILAG, British Isles Lupus Assessment Group (BILAG) index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.

  • Treatment analysis refers to corticosteroids, antimalarials and cytotoxic treatment.